Broadfin Capital LLC Raised Stake in Adamas Pharmaceuticals INC (ADMS) by $7.05 Million as Shares Declined

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Broadfin Capital Llc increased its stake in Adamas Pharmaceuticals Inc (ADMS) by 24.83% based on its latest 2018Q2 regulatory filing with the SEC. Broadfin Capital Llc bought 281,918 shares as the company’s stock declined 17.64% while stock markets rallied. The hedge fund held 1.42 million shares of the health care company at the end of 2018Q2, valued at $36.60M, up from 1.14 million at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be bullish on the $272.81 million market cap company. The stock decreased 0.30% or $0.03 during the last trading session, reaching $9.98. About 412,860 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 9.07% since December 8, 2017 and is uptrending. It has underperformed by 6.55% the S&P500.

Broadfin Capital Llc, which manages about $1.26B and $635.22M US Long portfolio, decreased its stake in Heron Therapeutics Inc (NASDAQ:HRTX) by 1.06 million shares to 519,787 shares, valued at $20.19 million in 2018Q2, according to the filing. It also reduced its holding in Integra Lifesciences Hldgs C (NASDAQ:IART) by 135,000 shares in the quarter, leaving it with 163,424 shares, and cut its stake in La Jolla Pharmaceutical Co (NASDAQ:LJPC).

More notable recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Benzinga.com which released: “Daily Biotech Pulse: Denali’s Positive Results, Novartis’ Substance Abuse Therapy Launch, Medtronic Earnings – Benzinga” on November 20, 2018, also Seekingalpha.com with their article: “Is Osmotica’s Drug A Major Threat To Adamas’s Gocovri? – Seeking Alpha” published on March 09, 2018, Nasdaq.com published: “Why Adamas Pharmaceuticals Fell Today – Nasdaq” on February 20, 2018. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were released by: Seekingalpha.com and their article: “Adamas Gets Beat Down For Beating Q3 Estimates – Seeking Alpha” published on November 11, 2018 as well as Seekingalpha.com‘s news article titled: “Adamas: Valuation Report – Seeking Alpha” with publication date: March 27, 2018.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 4 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Adamas Pharmaceuticals had 5 analyst reports since June 22, 2018 according to SRatingsIntel. The rating was downgraded by Bank of America to “Neutral” on Friday, October 5. The firm earned “Neutral” rating on Monday, November 5 by Mizuho. The company was maintained on Friday, June 22 by Mizuho.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.